List view / Grid view

fda

 

UCB and Amgen submit FDA application for Osteoporosis drug

22 July 2016 | By Niamh Louise Marriott, Digital Content Producer

UCB and Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational, monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture...